<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FINACEA - azelaic acid gel </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold"><span class="Emphasis">For Dermatologic Use 
Only-Not for Ophthalmic, Oral, or Intravaginal Use</span></span></p>
<p><span class="Bold"><span class="Emphasis">Rx only</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">FINACEA<span class="Sup">®</span> (azelaic acid) Gel, 15%, contains azelaic acid, 
a naturally occurring saturated dicarboxylic acid. Chemically, azelaic acid is 
1,7-heptanedicarboxylic acid, with the molecular formula C<span class="Sub">9</span> H<span class="Sub">16 </span>O<span class="Sub">4</span>, a 
molecular weight of 188.22, and the structural formula:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c5e836c-2851-4524-b91d-12ffadffd9ba&amp;name=chemical%20structure.jpg"></p>
<p>Azelaic acid is a white, odorless crystalline solid that is poorly soluble in 
water at 20°C (0.24%), but freely soluble in boiling water and in ethanol.</p>
<p>Each gram of FINACEA Gel, 15%, contains 0.15 gm azelaic acid (15% w/w) as the 
active ingredient in an aqueous gel base containing benzoic acid (as a 
preservative), disodium-EDTA, lecithin, medium-chain triglycerides, polyacrylic 
acid, polysorbate 80, propylene glycol, purified water, and sodium hydroxide to 
adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The mechanism(s) by which azelaic acid interferes with the 
pathogenic events in <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> are unknown.</p>
<a href="http://"></a><a href="http://"></a>Pharmacokinetics:<p>The percutaneous absorption of azelaic acid after topical 
application of FINACEA Gel, 15%, could not be reliably determined. Mean plasma 
azelaic acid concentrations in <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> patients treated with FINACEA Gel, 15%, 
twice daily for at least 8 weeks are in the range of 42 to 63.1 ng/mL. These 
values are within the maximum concentration range of 24.0 to 90.5 ng/mL observed 
in <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> patients treated with vehicle only. This indicates that FINACEA Gel, 
15%, does not increase plasma azelaic acid concentration beyond the range 
derived from nutrition and endogenous metabolism.</p>
<p><span class="Italics">In vitro</span> and human data suggest negligible 
cutaneous metabolism of <span class="Sup">3</span>H-azelaic acid 20% cream after 
topical application. Azelaic acid is mainly excreted unchanged in the urine, but 
undergoes some ß-oxidation to shorter chain dicarboxylic acids.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">FINACEA Gel, 15%, was evaluated for the treatment of mild to 
moderate papulopustular <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> in 2 clinical trials comprising a total of 664 
(333 active to 331 vehicle) patients. Both trials were multicenter, randomized, 
double-blind, vehicle-controlled 12-week studies with identical protocols. 
Overall, 92.5% of patients were Caucasian and 73% of patients were women, and 
the mean age was 49 (range 21 to 86) years. Enrolled patients had mild to 
moderate <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> with a mean lesion count of 18 (range 8 to 60) inflammatory 
<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>. Subjects without <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, with <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, 
rhinophyma, or ocular involvement, and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 
propylene glycol or to any other ingredients of the study drug were excluded. 
FINACEA Gel, 15%, or its vehicle were to be applied twice daily for 12 weeks; no 
other topical or systemic medication affecting the course of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> and/or 
evaluability was to be used during the studies. Patients were instructed to 
avoid spicy foods, thermally hot foods and drinks, and alcoholic beverages 
during the study, and to use only very mild soaps or soapless cleansing lotion 
for facial cleansing.</p>
<p>The primary efficacy endpoints were both</p>
<ol>
<li>change from baseline in inflammatory lesion counts and </li>
<li>success defined as a score of clear or minimal with at least a 2 step 
reduction from baseline on the Investigator's Global Assessment 
(IGA):</li>
</ol>
<a href="http://"></a><a name="ie1ab2bba-c7c1-43f9-8f47-66015533e019"></a><table border="1" width="494">
<col width="21%">
<col width="78%">
<tbody class="Headless">
<tr class="First">
<td>CLEAR:</td>
<td>No <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>; no or residual <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; 
no or mild to moderate <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
<tr>
<td>MINIMAL:</td>
<td>Rare <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>; residual to mild 
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; mild to moderate <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
<tr>
<td>MILD:</td>
<td>Few <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>; mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; mild to 
moderate <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
<tr>
<td>MILD TO MODERATE:</td>
<td>Distinct number of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>; mild to 
moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; mild to moderate <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
<tr>
<td>MODERATE:</td>
<td>Pronounced number of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>; moderate 
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; mild to moderate <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
<tr>
<td>MODERATE TO SEVERE:</td>
<td>Many <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, occasionally with large 
inflamed lesions; moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; moderate degree of <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
<tr class="Last">
<td><p class="First">SEVERE:</p></td>
<td>Numerous <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, occasionally with 
confluent areas of inflamed lesions; moderate or severe <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; moderate or 
severe <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span></td>
</tr>
</tbody>
</table>
<p>Primary efficacy assessment was based on the intent-to-treat (ITT) population 
with last observation carried forward (LOCF).</p>
<p>Both studies demonstrated a statistically significant difference in favor of 
FINACEA Gel, 15%, over its vehicle in reducing the number of inflammatory 
<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> associated with <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> (Table 1) and with success on the 
IGA in the ITT-LOCF population at the end of treatment.</p>
<a href="http://"></a><a name="i26f44586-a6ab-461e-8ee8-b4cf27d16016"></a><table border="1" width="548">
<caption><span>Table 1. Inflammatory <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">Papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">Pustules</span> (ITT population)<a href="#footnote-1">*</a></span></caption>
<col width="21%">
<col width="24%">
<col width="14%">
<col width="23%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<p class="First">Study One</p>
<p>FINACEA<span class="Sup">®</span> Gel,15%</p>N = 164</td>
<td>
<p class="First">Study One</p>
<p>VEHICLE</p>N = 165</td>
<td>
<p class="First">Study Two</p>
<p>FINACEA<span class="Sup">®</span> Gel,15%</p>N = 167</td>
<td>
<p class="First">Study Two</p>
<p>VEHICLE</p>
<p>N = 166</p>
</td>
</tr>
<tr>
<td>
<p class="First">Mean Lesion</p>
<p>Count</p>Baseline</td>
<td>17.5</td>
<td>17.6</td>
<td>17.9</td>
<td>18.5</td>
</tr>
<tr>
<td>
<p class="First">End of</p>Treatment<a href="#footnote-1">*</a>
</td>
<td>6.8</td>
<td>10.5</td>
<td>9.0</td>
<td>12.1</td>
</tr>
<tr class="Last">
<td>
<p class="First">Mean Percent</p>
<p>Reduction</p>
<p>End of</p>Treatment<a href="#footnote-1">*</a>
</td>
<td>57.9%</td>
<td>39.9%</td>
<td>50.0%</td>
<td>38.2%</td>
</tr>
</tbody>
</table>
<a href="#footnote-reference-1">*</a>ITT population with last observation carried forward (LOCF);<p>Although some reduction of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> which was present in patients with 
<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> occurred in clinical studies, efficacy for 
treatment of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> in the absence of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> has not 
been evaluated.</p>
<p>FINACEA Gel, 15%, was superior to the vehicle with regard to success based on 
the investigator's global assessment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> on a 7-point static score at the 
end of treatment, (ITT population; Table 2).</p>
<a href="http://"></a><a name="iabc30a0c-dee4-4d00-8541-fe329dbc2c1d"></a><table border="1" width="544">
<caption><span>Table 2. Investigator's Global Assessment at the End of Treatment<a href="#footnote-2">*</a></span></caption>
<col width="21%">
<col width="23%">
<col width="15%">
<col width="23%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<p class="First">Study One</p>
<p>FINACEA<span class="Sup">®</span> Gel, 15%</p>N = 164</td>
<td>
<p class="First">Study One</p>
<p>VEHICLE</p>N = 165</td>
<td>
<p class="First">Study Two</p>
<p>FINACEA<span class="Sup">®</span> Gel, 15%</p>N = 167</td>
<td>
<p class="First">Study Two</p>
<p>VEHICLE</p>
<p>N = 166</p>
</td>
</tr>
<tr class="Last">
<td>
<p class="First">CLEAR, MINIMAL</p>
<p>or MILD at End</p>
<p>of Treatment</p>(%of Patients)</td>
<td>61%</td>
<td>40%</td>
<td>61%</td>
<td>48%</td>
</tr>
</tbody>
</table>
<br><a href="#footnote-reference-2">*</a>ITT population with last observation carried forward (LOCF);</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">FINACEA Gel, 15%, is indicated for topical treatment of inflammatory <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and 
<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> of mild to moderate <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>. Although some reduction of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> which 
was present in patients with <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> occurred in 
clinical studies, efficacy for treatment of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> in the absence 
of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> has not been evaluated. Patients should be instructed to 
avoid spicy foods, thermally hot foods and drinks, alcoholic beverages and to 
use only very mild soaps or soapless cleansing lotion for facial cleansing.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">FINACEA Gel, 15%, is contraindicated in individuals with a history of 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to propylene glycol or any other component of the formulation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">FINACEA Gel, 15%, is for dermatologic use only, and not for 
ophthalmic, oral or intravaginal use.</p>
<p>There have been isolated reports of hypopigmentation after use of azelaic 
acid. Since azelaic acid has not been well studied in patients with dark 
complexion, these patients should be monitored for early signs of 
hypopigmentation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General:<p class="First">Contact with the eyes should be avoided. If sensitivity or severe 
irritation develops with the use of FINACEA Gel, 15%, treatment should be 
discontinued and appropriate therapy instituted.</p>
<a href="http://"></a><a href="http://"></a>Information For Patients<p>Patients using FINACEA Gel, 15%, should receive the following 
information and instructions:</p>
<ul>
<li>FINACEA Gel, 15%, is to be used only as directed by the physician. </li>
<li>FINACEA Gel, 15%, is for external use only. It is not to be used orally, 
intravaginally, or for the eyes. </li>
<li>Cleanse affected area(s) with a very mild soap or a soapless cleansing 
lotion and pat dry with a soft towel before applying FINACEA Gel, 15%. Avoid 
alcoholic cleansers, tinctures and astringents, abrasives and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> agents. 
</li>
<li>Avoid contact of FINACEA Gel, 15%, with the mouth, eyes and other mucous 
membranes. If it does come in contact with the eyes, wash the eyes with large 
amounts of water and consult a physician if <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> persists. </li>
<li>The hands should be washed following application of FINACEA Gel, 15%. </li>
<li>Cosmetics may be applied after FINACEA Gel, 15%, has dried. </li>
<li><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span> (e.g., <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>) may occur during use 
of FINACEA Gel, 15%, usually during the first few weeks of treatment. If 
irritation is excessive or persists, use of FINACEA Gel, 15%, should be 
discontinued, and patients should consult their physician (See <span class="Bold"><span class="Emphasis">ADVERSE REACTIONS</span></span>). </li>
<li>Avoid any foods and beverages that might provoke <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and 
blushing (including spicy food, alcoholic beverages, and thermally hot drinks, 
including hot coffee and tea). </li>
<li>Patients should report abnormal changes in skin color to their physician. 
</li>
<li>Avoid the use of occlusive dressings or wrappings.</li>
</ul>
<a href="http://"></a><a href="http://"></a>Drug interactions:<p>There have been no formal studies of the interaction of FINACEA 
Gel, 15%, with other drugs.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, mutagenesis, impairment of 
fertility:<p>Long-term animal studies have not been performed to evaluate the 
carcinogenic potential of FINACEA Gel, 15%. Azelaic acid was not mutagenic or 
clastogenic in a battery of <span class="Italics">in vitro</span> (Ames assay, 
HGPRT in V79 cells {Chinese hamster lung cells}, and chromosomal aberration 
assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and <span class="Italics">in vivo</span> (dominant 
lethal assay in mice and mouse micronucleus assay) genotoxicity tests.</p>
<p>Oral administration of azelaic acid at dose levels up to 2500 mg/kg/day (162 
times the maximum recommended human dose based on body surface area) did not 
affect fertility or reproductive performance in male or female rats.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy:<a href="http://"></a><a href="http://"></a>Teratogenic effects<a href="http://"></a><a href="http://"></a>Pregnancy Category B<p>There are no adequate and well-controlled studies of topically 
administered azelaic acid in pregnant women. The experience with FINACEA Gel, 
15%, when used by pregnant women is too limited to permit assessment of the 
safety of its use during pregnancy.</p>
<p>Dermal embryofetal developmental toxicology studies have not been performed 
with azelaic acid, 15%, gel. Oral embryofetal developmental studies were 
conducted with azelaic acid in rats, rabbits, and cynomolgus monkeys. Azelaic 
acid was administered during the period of organogenesis in all three animal 
species. Embryotoxicity was observed in rats, rabbits, and monkeys at oral doses 
of azelaic acid that generated some maternal toxicity. Embryotoxicity was 
observed in rats given 2500 mg/kg/day (162 times the maximum recommended human 
dose based on body surface area), rabbits given 150 or 500 mg/kg/day (19 or 65 
times the maximum recommended human dose based on body surface area) and 
cynomolgus monkeys given 500 mg/kg/day (65 times the maximum recommended human 
dose based on body surface area) azelaic acid. No teratogenic effects were 
observed in the oral embryofetal developmental studies conducted in rats, 
rabbits and cynomolgus monkeys.</p>
<p>An oral peri- and post-natal developmental study was conducted in rats. 
Azelaic acid was administered from gestational day 15 through day 21 postpartum 
up to a dose level of 2500 mg/kg/day. Embryotoxicity was observed in rats at an 
oral dose that generated some maternal toxicity (2500 mg/kg/day; 162 times the 
maximum recommended human dose based on body surface area). In addition, slight 
disturbances in the postnatal development of fetuses was noted in rats at oral 
doses that generated some maternal toxicity (500 and 2500 mg/kg/day; 32 and 162 
times the maximum recommended human dose based on body surface area). No effects 
on sexual maturation of the fetuses were noted in this study.</p>
<p>Because animal reproduction studies are not always predictive of human 
response, this drug should be used only if clearly needed during 
pregnancy.</p>
<a href="http://"></a><a href="http://"></a>Nursing mothers:<p>Equilibrium dialysis was used to assess human milk partitioning 
<span class="Italics">in vitro</span>. At an azelaic acid concentration of 25 
μg/mL, the milk/ plasma distribution coefficient was 0.7 and the milk/buffer 
distribution was 1.0, indicating that passage of drug into maternal milk may 
occur. Since less than 4% of a topically applied dose of azelaic acid cream, 
20%, is systemically absorbed, the uptake of azelaic acid into maternal milk is 
not expected to cause a significant change from baseline azelaic acid levels in 
the milk. However, caution should be exercised when FINACEA Gel, 15%, is 
administered to a nursing mother.</p>
<a href="http://"></a><a href="http://"></a>Pediatric use:<p>Safety and effectiveness of FINACEA Gel, 15%, in pediatric 
patients have not been established.</p>
<a href="http://"></a><a href="http://"></a>Geriatric use:<p>Clinical studies of FINACEA Gel, 15%, did not include sufficient 
numbers of subjects aged 65 and over to determine whether they respond 
differently from younger subjects.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Overall, treatment related adverse events, including burning, 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/ <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, dryness/tightness/scaling, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and 
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>/irritation/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, were 19.4% (24/124) for FINACEA Gel, 15%, and 7.1% 
(9/127) for the active comparator gel at 15 weeks.</p>
<p>In two vehicle controlled, and one active controlled U.S. clinical studies, 
treatment safety was monitored in 788 patients who used twice daily FINACEA Gel, 
15%, for 12 weeks (N=333) or for 15 weeks (N=124), or the gel vehicle (N=331) 
for 12 weeks</p>
<a href="http://"></a><a name="ib6ac75a0-616e-4401-8f30-dc01ae1e15d8"></a><table border="1" width="522">
<caption><span>Table 3. Cutaneous Adverse Events Occurring in ≥1% of Subjects in the 
<span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">Rosacea</span> Trials by Treatment Group and Maximum Intensity<a href="#footnote-3">*</a></span></caption>
<col width="22%">
<col width="13%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<p class="First">FINACEA® Gel, 15%</p>
<p>N=457 (100%)</p>
</td>
<td>
<p class="First">Vehicle</p>N=331 (100%)</td>
</tr>
<tr>
<td>
<p class="First">Mild</p>
<p>n=99</p>(22%)</td>
<td>
<p class="First">Moderate</p>
<p>n=61</p>(13%)</td>
<td>
<p class="First">Severe</p>
<p>n=27</p>(6%)</td>
<td>
<p class="First">Mild</p>
<p>n=46</p>(14%)</td>
<td>
<p class="First">Moderate</p>
<p>n=30</p>(9%)</td>
<td>
<p class="First">Severe</p>
<p>n=5</p>
<p>(2%)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Burning/</p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/</p><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span></td>
<td>71 (16%)</td>
<td>42 (9%)</td>
<td>17 (4%)</td>
<td>8 (2%)</td>
<td>6 (2%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td>29 (6%)</td>
<td>18 (4%)</td>
<td>5 (1%)</td>
<td>9 (3%)</td>
<td>6 (2%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>
<p class="First">Scaling/dry</p>skin/xerosis </td>
<td>21 (5%)</td>
<td>10 (2%)</td>
<td>5 (1%)</td>
<td>31 (9%)</td>
<td>14 (4%)</td>
<td>1 (less than 1%)</td>
</tr>
<tr>
<td>
<p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>/</p>irritation</td>
<td>6 (1%)</td>
<td>7 (2%)</td>
<td>2 (less than 1%)</td>
<td>8 (2%)</td>
<td>4 (1%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>
<p class="First">Contact</p><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> </td>
<td>2 (less than 1%)</td>
<td>3 (1%)</td>
<td>0 (0%)</td>
<td>1 (less than 1%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </td>
<td>3 (1%)</td>
<td>2 (less than 1%)</td>
<td>0 (0%)</td>
<td>3 (1%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></td>
<td>3 (1%)</td>
<td>1 (less than 1%)</td>
<td>0 (0%)</td>
<td>1 (less than 1%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>
<a href="#footnote-reference-3">*</a>Subjects may have greater than 1 cutaneous adverse event; thus, the sum of the 
frequencies of preferred terms may exceed the number of subjects with at least 1 
cutaneous adverse event.<p>FINACEA Gel, 15%, and its vehicle caused irritant reactions at the 
application site in human dermal safety studies. FINACEA Gel, 15%, caused 
significantly more irritation than its vehicle in a cumulative irritation study. 
Some improvement in irritation was demonstrated over the course of the clinical 
studies, but this improvement might be attributed to subject dropouts. No 
<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> or photoallergenicity were reported in human dermal safety 
studies.</p>
<p>In patients using azelaic acid formulations, the following additional adverse 
experiences have been reported rarely: worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="138502" conceptname="Vitiligo">vitiligo</span> 
depigmentation, small depigmented spots, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, reddening (signs of 
<span class="product-label-link" type="condition" conceptid="4197127" conceptname="Keratosis pilaris">keratosis pilaris</span>), and exacerbation of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>.</p>
<p>Post-marketing safety-Skin: facial burning and irritation; Eyes: 
<span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span> on accidental exposure with FINACEA Gel, 15%, to the eye (see 
<span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">FINACEA Gel, 15%, is intended for cutaneous use only. If pronounced local 
irritation occurs, patients should be directed to discontinue use and 
appropriate therapy should be instituted (See <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">A thin layer of FINACEA Gel, 15%, should be gently massaged into the affected 
areas on the face twice daily, in the morning and evening. Patients should be 
reassessed if no improvement is observed upon completing 12 weeks of therapy.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">FINACEA® Gel, 15%, is supplied in tubes in the following size: 
</p>
<p>50 g - NDC 54868-5236-1</p>
<p><span class="Bold"><span class="Emphasis"><br></span></span></p>
<p><span class="Bold"><span class="Emphasis">Storage</span></span></p>
<p>Store at 25°C (77°F); excursions permitted between 15-30°C (59-86°F) [See USP 
Controlled Room Temperature]. </p>
<p>Distributed under license; <span class="Italics">U.S. Patent No 
4,713,394</span></p>
<p>© 2005, Intendis, Inc. All rights reserved. </p>
<p>May 2005 </p>
<p><br></p>
<p>Manufactured by Intendis Manufacturing S.p.A., Segrate, Milan, Italy </p>
<p>Distributed by: INTENDIS Pine Brook, NJ 07058 </p>
<p>6058301 2540870</p>
<br><p><span class="Bold">Relabeling of "Additional" barcode label by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">FINACEA® Gel, 15% 
</p>
<p>50 g</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c5e836c-2851-4524-b91d-12ffadffd9ba&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FINACEA 		
					</strong><br><span class="contentTableReg">azelaic acid gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5236(NDC:10922-825)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AZELAIC ACID</strong> (AZELAIC ACID) </td>
<td class="formItem">AZELAIC ACID</td>
<td class="formItem">0.15 g  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZOIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5236-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021470</td>
<td class="formItem">03/03/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>484a0faa-15e4-4004-9d85-0d6e798da9a5</div>
<div>Set id: 6c5e836c-2851-4524-b91d-12ffadffd9ba</div>
<div>Version: 1</div>
<div>Effective Time: 20100831</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
